Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: The Pandemic Cannot Mask Roche’s Weaknesses

Declining COVID-19 Sales, Biosimilar Exposure And Pipeline Failures Bite

Executive Summary

Declining COVID-19-related diagnostic and therapeutic sales are likely to expose long-standing weaknesses and amplify the effects of new pressures that were masked during the pandemic.

You may also be interested in...



Novartis’s Kesimpta Already A Big Earner But Leqvio Is Slow Burner

Novartis’s multiple sclerosis treatment Kesimpta has shot out of the gates and bidding fair to contribute generously to the firm’s coffers, while new cholesterol drug Leqvio struggles, Q1 results show.

Roche's SERD Setback Means Menarini Retains An Edge

Roche's giredestrant failed to show a benefit on progression-free survival in the Phase II acelERA trial in people with advanced breast cancer.

Stock Watch: Second-Order Pandemic Effects In J&J’s First Quarter

The second-order pandemic effects on labor and logistics that have plagued other sectors appeared across J&J’s earnings announcement. With the biggest impact at its consumer business, why then has demand for J&J’s COVID-19 vaccine plummeted?

Topics

Related Companies

UsernamePublicRestriction

Register

SC146305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel